H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Sarepta (SRPT) with a Sell rating and $80 price target The firm considers Elevidys consensus estimates to be too high. Elevidys consensus estimates of $2.14B in 2025 is aggressive, considering the modest clinical efficacy profile of the product observed to date and the limited evidence to support use across the entire Duchenne muscular dystrophy population, the analyst tells investors in a research note. H.C. Wainwright believes “lofty” consensus numbers in 2025 and beyond imply significant commercial uptake of Elevidys in older patients and non-ambulatory patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta recent weakness brings buying opportunity, says JPMorgan
- Qualcomm, Moderna report quarterly beats: Morning Buzz
- JPMorgan, Five Below downgraded: Wall Street’s top analyst calls
- Sarepta price target raised to $150 from $148 at Guggenheim
- Sarepta price target lowered to $193 from $200 at Baird